Earnings Preview — 5182 total
Damora Therapeutics walks into its May 14 earnings release with short sellers having nearly doubled their positions in six weeks — a striking build in a small-cap biotech that has already shed 11% over the past…
HYLIION heads into its Q1 2026 earnings today with the market sending a strikingly bullish signal — but short sellers are not yet convinced. The options market is the loudest voice here. The put/call ratio has dropped…
Bolt Biotherapeutics reports Q1 2026 results today with one striking data point: short sellers have largely abandoned their positions, even as the stock remains near $4.78 and the company continues to burn cash. The…
SOBR Safe enters its May 14 earnings report in one of the most aggressively positioned lending environments visible in the micro-cap universe. The borrow story here is the standout. Cost to borrow has exploded to 534%…
Inhibikase Therapeutics enters its May 15 earnings report as one of the most heavily shorted small-cap biotechs in its peer group — yet analysts are unambiguously bullish, creating a tension the quarterly print will…
RVYL enters its May 15 earnings report having already done something remarkable: the stock gained 48% in a single month, and 16% on Tuesday alone, arriving at $7.81 with the momentum firmly at the bulls' backs. The…
Zentalis Pharmaceuticals enters its May 14 earnings report with short sellers meaningfully more active than they were a month ago — and options traders signalling the opposite of fear. Short interest has climbed…
Virgin Galactic heads into its May 14 earnings report carrying one of the most heavily shorted positions in the entire market, even as the lending pool has loosened and options traders lean conspicuously bullish. Short…
Cyclerion Therapeutics heads into its May 15 earnings report with a borrow market that has loosened sharply — even as the cost to borrow remains extraordinarily high. The most striking shift in the lending data is not…
Nocera, Inc. heads into Thursday's earnings release with a collapsing share price, elevated borrow costs, and a borrow market that has tightened meaningfully over the past month. The lending story is the sharpest…
KLXE heads into its May 13 print on the back of a 73% surge in one month, a move that towers over every correlated peer in the oilfield services space. The rally's origin story sits in the insider register. The acting…
CANG reports May 14 with short sellers adding positions heading into the print — but the lending market tells a more nuanced story than the headline suggests. Short interest has climbed to 2.1% of the free float, up…
DXF heads into its May 15 earnings release having just staged a 42% single-day rally — and then lost a fifth of its value over the preceding month. That price action alone tells the story of a deeply unsettled stock.…
One Stop Systems reports Q1 2026 earnings today with one of the more charged setups in the small-cap hardware space: the stock has gained roughly 99% over the past month and 59% in the past week alone, closing at…
Daré Bioscience walks into tomorrow's earnings print carrying the fastest short-interest build of any comparable window in recent months — a signal that at least some traders are betting the strong May rally has run…
Co-Diagnostics heads into its May 14 earnings report with its lending market under the most stress it has seen in months — and the short score to match. The borrow market tells the sharpest story. Cost to borrow has…
Savara Inc. walks into tonight's earnings with one of the more heavily shorted profiles in small-cap biotech, and bears have been adding to that position all month. Short interest is running at 13.5% of the free float…
AnaptysBio reports Q1 results on May 15 with short sellers quietly adding pressure just as the stock trades near its lowest level in months. The short interest angle is the standout setup heading into this print. Bears…
Intellia Therapeutics reports after the close on May 14 with more than a third of its free float sold short — a level that makes the lending market the most important context for tomorrow's print. Short interest has…
REGENXBIO heads into its May 14 earnings release with short sellers slowly backing away — but by no means conceding the debate. Short interest tells the headline story. At 13.1% of free float, the short position is…
